Amgen Inc. AMGN
NASDAQ · Healthcare · Drug Manufacturers - General
$435.64
Close on Fri, 20 Nov 2026 · market value $236B
What the price is betting on
Below its recordAt $436, the price assumes revenue grows about 2.9% a year for five years, from $38.9B to about $43.9B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 7.1% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than AMGN? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$432
Base
$483
Bull
$541
Today $436
- Bear $432. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $483. Cash flow grows 5% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $541. Cash flow grows 7% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$39.2B$39.5B, on the path
- FY2027$40.3B$41.3B, on the path
- FY2028$41.5B$43.3B, on the path
- FY2029$42.6B$45.1B, on the path
- FY2030$43.9B$47.5B, on the path
Each year's revenue at 2.9% growth from $38.9B in the 12 months to September 2026.
At a glance
Healthcare · Drug Manufacturers - General · listed on NASDAQ
- Revenue, FY2025
- $36.7B
- Growth, 3 years a year
- 12%
- Cash margin
- 22%
- Net debt
- $45.5B
- Shares, 3-year change
- +0.2%
- Dividend yield
- 2.2%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.